{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T22:27:33Z","timestamp":1786660053827,"version":"build-2736575974"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:00:00Z","timestamp":1771372800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:00:00Z","timestamp":1771372800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100004331","name":"Johnson and Johnson","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Prostate Cancer Prostatic Dis"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1038\/s41391-026-01086-8","type":"journal-article","created":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T16:36:28Z","timestamp":1771432588000},"page":"539-542","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Navigating drug\u2013drug interactions with apalutamide"],"prefix":"10.1038","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6806-1294","authenticated-orcid":false,"given":"Bilal A.","family":"Siddiqui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karine","family":"Tawagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Caulfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pankaj","family":"Aggarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5990-298X","authenticated-orcid":false,"given":"Tanya","family":"Dorff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,18]]},"reference":[{"key":"1086_CR1","unstructured":"Society AC. Cancer facts & figures 2024. 2024. https:\/\/www.cancer.org\/content\/dam\/cancer-org\/research\/cancer-facts-and-statistics\/annual-cancer-facts-and-figures\/2024\/2024-cancer-facts-and-figures-acs.pdf"},{"key":"1086_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.103736","volume":"9","author":"H Bolek","year":"2024","unstructured":"Bolek H, Yazgan SC, Yekeduz E, Kaymakcalan MD, McKay RR, Gillessen S, et al. Androgen receptor pathway inhibitors and drug-drug interactions in prostate cancer. ESMO Open. 2024;9:103736.","journal-title":"ESMO Open"},{"key":"1086_CR3","unstructured":"ERLEADA\u00ae [prescribing information]. Horsham, PA: Janssen Products, LP; 2024. https:\/\/www.jnjlabels.com\/package-insert\/product-monograph\/prescribing-information\/ERLEADA-pi.pdf"},{"key":"1086_CR4","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1056\/NEJMoa1903307","volume":"381","author":"KN Chi","year":"2019","unstructured":"Chi KN, Agarwal N, Bjartell A, Chung BH, Pereira de Santana Gomes AJ, Given R, et al. Apalutamide for metastatic, castration-sensitive prostate cancer. N Engl J Med. 2019;381:13\u201324.","journal-title":"N Engl J Med"},{"key":"1086_CR5","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.eururo.2020.08.011","volume":"79","author":"MR Smith","year":"2021","unstructured":"Smith MR, Saad F, Chowdhury S, Oudard S, Hadaschik BA, Graff JN, et al. Apalutamide and overall survival in prostate cancer. Eur Urol. 2021;79:150\u20138.","journal-title":"Eur Urol"},{"key":"1086_CR6","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1016\/S1470-2045(11)70040-7","volume":"12","author":"J Lees","year":"2011","unstructured":"Lees J, Chan A. Polypharmacy in elderly patients with cancer: clinical implications and management. Lancet Oncol. 2011;12:1249\u201357.","journal-title":"Lancet Oncol"},{"key":"1086_CR7","doi-asserted-by":"crossref","unstructured":"Zhao M, Ma J, Li M, Zhang Y, Jiang B, Zhao X, et al. Cytochrome P450 enzymes and drug metabolism in humans. Int J Mol Sci. 2021;22:12808.","DOI":"10.3390\/ijms222312808"},{"key":"1086_CR8","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/nrd3028","volume":"9","author":"C International Transporter","year":"2010","unstructured":"International Transporter C, Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, et al. Membrane transporters in drug development. Nat Rev Drug Discov. 2010;9:215\u201336.","journal-title":"Nat Rev Drug Discov"},{"key":"1086_CR9","unstructured":"XTANDI\u00ae [prescribing information]. Northbrook, IL: Astellas Pharma US, Inc.; 2025. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/213674s011,203415s023lbl.pdf"},{"key":"1086_CR10","unstructured":"NUBEQA\u00ae [prescribing information]. Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc.; 2025. https:\/\/labeling.bayerhealthcare.com\/html\/products\/pi\/Nubeqa_PI.pdf"},{"key":"1086_CR11","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1007\/s11523-025-01139-3","volume":"20","author":"J De La Cerda","year":"2025","unstructured":"De La Cerda J, Belkoff L, Courtney KD, Diamond E, D\u2019Olimpio J, Dunshee C, et al. Safety and tolerability of relugolix in combination with abiraterone or apalutamide for treatment of patients with advanced prostate cancer: data from a 52-week clinical trial. Target Oncol. 2025;20:503\u201317.","journal-title":"Target Oncol"},{"key":"1086_CR12","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.120.017559","volume":"9","author":"A Chen","year":"2020","unstructured":"Chen A, Stecker E, Warden BA. Direct oral anticoagulant use: a practical guide to common clinical challenges. J Am Heart Assoc. 2020;9:e017559.","journal-title":"J Am Heart Assoc"},{"key":"1086_CR13","doi-asserted-by":"crossref","unstructured":"Leblanc K, Edwards SJ, Dranitsaris G, Leong DP, Carrier M, Malone S, et al. Drug interactions between androgen receptor axis-targeted therapies and antithrombotic therapies in prostate cancer: Delphi consensus. Cancers. 2024;16:3336.","DOI":"10.3390\/cancers16193336"},{"key":"1086_CR14","first-page":"445","volume":"12","author":"R Potdar","year":"2022","unstructured":"Potdar R, Gartrell BA, Given R, Karsh L, Frankel J, Nenno K, et al. Concomitant use of oral anticoagulants in patients with advanced prostate cancer receiving apalutamide: a post-hoc analysis of TITAN and SPARTAN studies. Am J Cancer Res. 2022;12:445\u201350.","journal-title":"Am J Cancer Res"},{"key":"1086_CR15","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1001\/jama.2022.12138","volume":"328","author":"R Chou","year":"2022","unstructured":"Chou R, Cantor A, Dana T, Wagner J, Ahmed AY, Fu R, et al. Statin use for the primary prevention of cardiovascular disease in adults: updated evidence report and systematic review for the US Preventive Services Task Force. JAMA. 2022;328:754\u201371.","journal-title":"JAMA"},{"key":"1086_CR16","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1002\/cpt.903","volume":"103","author":"DJ Brackman","year":"2018","unstructured":"Brackman DJ, Giacomini KM. Reverse translational research of ABCG2 (BCRP) in human disease and drug response. Clin Pharmacol Ther. 2018;103:233\u201342.","journal-title":"Clin Pharmacol Ther"},{"key":"1086_CR17","doi-asserted-by":"publisher","first-page":"e2527988","DOI":"10.1001\/jamanetworkopen.2025.27988","volume":"8","author":"S Roy","year":"2025","unstructured":"Roy S, Ozay ZI, Guha A, Sun Y, Chi KN, Morgan SC, et al. Statin use in patients with advanced prostate cancer in the TITAN and SPARTAN trials. JAMA Netw Open. 2025;8:e2527988.","journal-title":"JAMA Netw Open"},{"key":"1086_CR18","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1056\/NEJMoa2004325","volume":"382","author":"ND Shore","year":"2020","unstructured":"Shore ND, Saad F, Cookson MS, George DJ, Saltzstein DR, Tutrone R, et al. Oral relugolix for androgen-deprivation therapy in advanced prostate cancer. N Engl J Med. 2020;382:2187\u201396.","journal-title":"N Engl J Med"},{"key":"1086_CR19","unstructured":"ORGOVYX (relugolix) tablets [package insert]. Horsham, PA: Janssen Biotech, Inc.; 2024."},{"key":"1086_CR20","doi-asserted-by":"crossref","unstructured":"Brown G, Belkoff L, Hafron J, Aggarwal P, Potdar R, Bhaumik A, et al. Maintenance of castration with concomitant relugolix and apalutamide (Apa) in patients with high-risk localized prostate cancer (HR-LPC): 1 year update. J Clin Oncol. 2023;41:e17094.","DOI":"10.1200\/JCO.2023.41.16_suppl.e17094"}],"updated-by":[{"DOI":"10.1038\/s41391-026-01104-9","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T00:00:00Z","timestamp":1773878400000}}],"container-title":["Prostate Cancer and Prostatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41391-026-01086-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41391-026-01086-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41391-026-01086-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T21:44:56Z","timestamp":1786657496000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41391-026-01086-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,18]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["1086"],"URL":"https:\/\/doi.org\/10.1038\/s41391-026-01086-8","relation":{},"ISSN":["1365-7852","1476-5608"],"issn-type":[{"value":"1365-7852","type":"print"},{"value":"1476-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,18]]},"assertion":[{"value":"1 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 January 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2026","order":6,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":7,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"In this article, in column 2, row 4 of Table 1 \u201cInducer (weak)\u201d should be changed to \u201cInducer (strong)\u201d.","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2026","order":9,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":10,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41391-026-01104-9","URL":"https:\/\/doi.org\/10.1038\/s41391-026-01104-9","order":12,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Bilal A. Siddiqui has received consulting\/advisory fees from Amgen, Bayer, Merck, Pfizer, Johnson & Johnson, SurvivorNet; honoraria fees from Cancer Expert Now, Curio Science, Cardinal Health, DAVA Oncology; researching funding (to individual) from\u00a0ASCO-Conquer Cancer Foundation, Prostate Cancer Foundation, Cancer Research Institute; research funding (to institution) from\u00a0Amgen, Johnson & Johnson, Regeneron; travel expenses from Merck, Curio Science, Cardinal Health. Karine Tawagi has received consulting\/advisory fees from AstraZeneca, Seagen, Astellas, Pfizer; speaker fees from AstraZeneca; honoraria fees from GU Oncology Now, OncLive, Curio Science, Ideology Health, DAVA Oncology, Cardinal Health, Signify MD. Sarah Caulfield has nothing to disclose. Pankaj Aggarwal is a full-time employee and shareholder of Johnson & Johnson. Tanya Dorff has received consulting\/advisory fees from Astellas, AstraZeneca, Bayer, Dendreon, Janssen, Pfizer, Novartis; research funding (to institution) from AbbVie, Amgen, AstraZeneca, Dendreon.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}